146 related articles for article (PubMed ID: 37920875)
21. A Global Phase I Clinical Study Comparing the Safety and Pharmacokinetics of Proposed Biosimilar BAT1706 and Bevacizumab (Avastin
Wu X; Wynne C; Xu C; Gan Y; Wang C; Thomas BE; Yu JC; Li S; Zhang L
BioDrugs; 2019 Jun; 33(3):335-342. PubMed ID: 31016568
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics, safety, tolerability, and immunogenicity of FKB238, a new biosimilar of bevacizumab, in healthy participants.
Boyce M; Wilkes D; Kaito H; Takanuma M; Arai Y
Int J Clin Pharmacol Ther; 2022 Jun; 60(6):280-290. PubMed ID: 35361328
[TBL] [Abstract][Full Text] [Related]
23. A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects.
Liu YN; Huang J; Guo C; Yang S; Ye L; Wu ST; Zhang XF; Yang XY; Han CC; Pei Q; Huang L; He QN; Yang GP
Cancer Chemother Pharmacol; 2020 Mar; 85(3):555-562. PubMed ID: 31907645
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus Reference Rituximab in Biologics-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis: A Double-Blind, Randomized, Three-Arm Study.
Haridas VM; Katta R; Nalawade A; Kharkar S; Zhdan V; Garmish O; Lopez-Lazaro L; Batra SS; Kankanwadi S
BioDrugs; 2020 Apr; 34(2):183-196. PubMed ID: 32052313
[TBL] [Abstract][Full Text] [Related]
25. A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab.
Demarchi M; Coliat P; Barthelemy P; Schott R; BenAbdelghani M; Kim M; Hii JCS; Feyaerts P; Ang FRX; Derde MP; Deforce F; Petit T; Schwabe C; Wynne C; Park LS; Pivot X
PLoS One; 2021; 16(9):e0248222. PubMed ID: 34555031
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study.
Yu KS; Kim B; Shin D; Park MK; Hwang JG; Kim MG; Chung H; Ghim J; Chung JY; Smolen JS; Burmester GR; Kim S; Bae Y; Jeon D; Yoo J; Yang G; Bae J; Keystone E
Expert Opin Investig Drugs; 2023 May; 32(5):429-439. PubMed ID: 37231670
[TBL] [Abstract][Full Text] [Related]
27. Tolerance, variability, and pharmacokinetics of bevacizumab biosimilars in Chinese healthy male subjects.
Zhang H; Li Q; Zhu X; Li C; Li X; Liu C; Hu Y; Chen G; Wei H; Wang J; Shen Z; Ding Y
Cancer Chemother Pharmacol; 2018 Oct; 82(4):615-623. PubMed ID: 30043208
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.
Hillson J; Mant T; Rosano M; Huntenburg C; Alai-Safar M; Darne S; Palmer D; Pavlova BG; Doralt J; Reeve R; Goel N; Weilert D; Rhyne PW; Chance K; Caminis J; Roach J; Ganguly T
Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417761
[TBL] [Abstract][Full Text] [Related]
29. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects.
Hyland E; Mant T; Vlachos P; Attkins N; Ullmann M; Roy S; Wagner V
Br J Clin Pharmacol; 2016 Oct; 82(4):983-93. PubMed ID: 27285856
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic bioequivalence, safety, and immunogenicity of GB222, a bevacizumab biosimilar candidate, and bevacizumab in Chinese healthy males: a randomized clinical trial.
Dong W; Chen M; Niu S; Wang B; Xia L; Wang J; Shen T; Wang Q; Lv J; Liu G; Fan H; Xie Z; Xie F; An Y; Zheng Q; Rao H; Song H; Fang Y
Expert Opin Biol Ther; 2022 Feb; 22(2):253-262. PubMed ID: 34236011
[TBL] [Abstract][Full Text] [Related]
31. A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST).
Wynne C; Schwabe C; Lemech C; Stroissnig H; Dias R; Sobierska J; Guenzi E; Otto H; Sattar A; Kay R; Haliduola HN; Berti F
Expert Opin Investig Drugs; 2022 Sep; 31(9):965-976. PubMed ID: 35107050
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects.
Zhang Q; Sun C; Wu J; Wu J; Zhang X; Liu Y; Dou C; Qin H; Zhang Q; Zhou R; Hu W
Expert Opin Biol Ther; 2023; 23(8):727-735. PubMed ID: 36880118
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics, Tolerability, Safety, and Immunogenicity of LY01008 and Bevacizumab (Avastin®) in Healthy Chinese Subjects.
Xie L; Zhu Y; Liang Z; Zhao Y; Zhou S; Chen J; Zhang H; Ding S; Wang L; Shao F
Eur J Drug Metab Pharmacokinet; 2022 May; 47(3):309-317. PubMed ID: 35112328
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic equivalence of CT-P17 to high-concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects.
Yu KS; Jang IJ; Lim HS; Hong JH; Kim MG; Park MK; Cho DY; Park MS; Chung JY; Ghim JL; Lee S; Yoon SK; Kwon IS; Lee SJ; Kim SH; Bae YJ; Cha JB; Furst DE; Keystone E; Kay J
Clin Transl Sci; 2021 Jul; 14(4):1280-1291. PubMed ID: 33503313
[TBL] [Abstract][Full Text] [Related]
35. A randomized, double-blind, 3-arm, parallel study assessing the pharmacokinetics, safety, tolerability and immunogenicity of AVT04, an ustekinumab candidate biosimilar, in healthy adults.
Wynne C; Hamilton P; McLendon K; Stroissnig H; Smith M; Duijzings P; Ruffieux R; Otto H; Sattar A; Haliduola HN; Leutz S; Berti F
Expert Opin Investig Drugs; 2023 May; 32(5):417-427. PubMed ID: 37212315
[TBL] [Abstract][Full Text] [Related]
36. A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumab.
Waller CF; Vutikullird A; Lawrence TE; Shaw A; Liu MS; Baczkowski M; Sharma R; Barve A; Goyal P; Donnelly C; Sengupta N; Pennella EJ
Br J Clin Pharmacol; 2018 Oct; 84(10):2336-2343. PubMed ID: 29926514
[TBL] [Abstract][Full Text] [Related]
37. A Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of SCT510 to Bevacizumab (Avastin
Wu J; Wu G; Xie L; Lv D; Xu C; Zhou H; Wu L; Zhang J; Shentu J
Drugs R D; 2023 Jun; 23(2):175-183. PubMed ID: 37247166
[TBL] [Abstract][Full Text] [Related]
38. A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects.
Liu Z; Gao Z; Yang W; Zhang L; Xiao N; Qu D; Su Z; Xu K; Liu G; Wang Y; Ren Q; Yu S; Cheng Y; Zhou Y; Deng Q; Zhao Y; Wang Z; Yang H
Expert Opin Drug Metab Toxicol; 2022; 18(7-8):519-527. PubMed ID: 35961948
[TBL] [Abstract][Full Text] [Related]
39. A randomized, double-blind, three-arm, parallel group, single-dose phase I study to evaluate the pharmacokinetic similarity between SB12 (a proposed eculizumab biosimilar) and eculizumab (Soliris) in healthy subjects.
Lee HA; Jang H; Jeong D; Kim Y; Fuhr R
Int J Clin Pharmacol Ther; 2022 Jun; 60(6):269-279. PubMed ID: 35348111
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double-blind, parallel-controlled, phase 1 study.
Zhang H; Wu M; Sun J; Zhu X; Li C; Ding Y; Zhang X; Chai K; Li X
Pharmacol Res Perspect; 2021 Apr; 9(2):e00733. PubMed ID: 33682358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
